Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

So what: The stock has pulled back in recent weeks on valuation concerns, but today's wide third-quarter beat -- loss of $0.03 per share on revenue of $26.2 million versus the consensus $0.25 loss and $18.3 million top line -- reignites enthusiasm over its path to profitability. In fact, total prescriptions for its Horizon's franchise Duexis and Rayos drugs increased 17.6% and 12.9%, respectively, giving analysts plenty of good vibes over its competitive position going forward.

Now what: Don't expect the growth to slow any time soon.

"We achieved continued acceleration in prescriptions and revenue in the third quarter, with both DUEXIS and RAYOS seeing significant growth in net revenue on a sequential quarter over quarter basis," said Chairman and CEO Timothy Walbert. "This sales growth, along with improvement in the bottom line and cash burn, continues our momentum toward becoming a profitable company."

Of course, with Horizon shares now up about 140% over their 52-week lows, Fools will need plenty of biotech savvy to estimate how much of that momentum is already baked into the price.